Major Flu Vaccines Go Out of Stock in Islamabad
Residents of Islamabad are facing a shortage of influenza vaccines as winter approaches, with several major brands unavailable at pharmacies across the federal capital. Three commonly used flu vaccines, Sinovac, Vaxigrip, and Influvac, are currently unavailable in the local market, leaving many residents unable to get vaccinated ahead of the flu season.
According to reports, several residents have visited multiple pharmacies over the past month but have been unable to find the vaccines. This sudden disappearance of standard preventative immunisations has caused concern among public health advocates and everyday citizens who rely on annual shots to protect themselves against circulating respiratory viruses during the colder months.
Why Are Flu Vaccines Unavailable in Islamabad?
A senior Health Ministry official attributed the shortage to international supply disruptions and rising prices. The official explained that transportation problems linked to the Iran-US war have affected global vaccine supplies, while higher import and transportation costs have made it difficult for suppliers to sell vaccines within Pakistan's pricing restrictions. These macroeconomic pressures and geopolitical tensions have created a bottleneck in the international pharmaceutical supply chain, preventing shipments from reaching local distributors in a timely manner.
Furthermore, stringent regulatory price caps set by domestic authorities often clash with fluctuating global shipping expenses. When international freight rates surge, pharmaceutical importers find it economically unviable to bring lower-priced regulated products into the country under existing retail ceilings. This dynamic has severely limited the availability of vital medical goods in urban centers like Islamabad, where demand spikes significantly during the autumn and winter transition.
When Will Sinovac and Other Vaccines Return?
Drug Regulatory Authority of Pakistan (DRAP) CEO Dr. Obaidullah Malik confirmed that the Chinese Sinovac vaccine is expected to become available by November 15. This projected arrival date offers a measure of relief for patients who specifically prefer or require this particular formulation, though health authorities advise checking local pharmacy inventories closer to the middle of the month.
At the same time, the Health Ministry official confirmed that the French vaccine Vaxigrip and American vaccine Influvac would not be available in Pakistan this year. The complete absence of these two prominent Western brands for the remainder of the season means that local physicians must guide their patients toward alternative preventative options where accessible.
Pricing Discrepancy Concerns With Virionza
Meanwhile, Virionza, another seasonal influenza vaccine available in the market, has raised concerns over a pricing discrepancy. The vaccine's packaging lists a maximum retail price of Rs. 1,304, while its DRAP barcode shows Rs. 654. This noticeable gap between the physical label and the scanned electronic price has created confusion among consumers and pharmacists alike.
A Health Ministry official attributed the difference to a possible error in the barcode system and maintained that the manufacturer was selling the vaccine at the correct price. Federal Health Minister Mustafa Kamal said he would investigate the pricing discrepancy. He also clarified that flu vaccines remain available in the market, although several major brands are currently unavailable.
Understanding the Regulatory Role of DRAP
The Drug Regulatory Authority of Pakistan oversees the manufacture, import, export, storage, distribution, and sale of therapeutic goods in the country. Established to ensure that medicines meeting safety, efficacy, and quality standards reach the public, DRAP also monitors maximum retail prices. When global supply chains experience shocks, regulatory bodies face the difficult task of balancing affordable access for citizens with commercial viability for international drug manufacturers.
The current situation highlights the vulnerability of domestic medical markets to overseas logistical failures. Regional conflicts and fuel price fluctuations directly impact the cost of moving temperature-sensitive biological products across international borders. As health officials work to resolve these distribution hurdles, patients are advised to consult their healthcare providers about safe and effective alternatives for seasonal immunisation.
